All In Biotech

Drug Trial Radar · NCT03267433

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 689 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

689

Planned (sponsor's estimate)

Start

Nov 27, 2017

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Aug 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.

Conditions

  • Mantle Cell Lymphoma

Interventions

  • Autologous Hematopoietic Stem Cell TransplantationProcedure

    Undergo HCT

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirateProcedure

    Undergo bone marrow biopsy and aspirate

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspirate

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • Positron Emission TomographyProcedure

    Undergo PET or PET/CT

  • RituximabBiological

    Given IV

  • Rituximab and Hyaluronidase HumanBiological

    Given SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative complete remission (CR) who undergo auto-hematopoietic stem cell transplant (HCT) followed by rituximab versus (vs.) maintenance rituximab aloneTime frame: Time between randomization and death from any cause, assessed up to 10 years

Locations

375 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • PCR Oncology

    Arroyo Grande, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • BASS Medical Group - Lennon

    Walnut Creek, California

  • Rocky Mountain Cancer Centers-Aurora

    Aurora, Colorado

  • The Medical Center of Aurora

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Boulder Community Foothills Hospital

    Boulder, Colorado

  • Rocky Mountain Cancer Centers-Boulder

    Boulder, Colorado

  • Rocky Mountain Cancer Centers - Centennial

    Centennial, Colorado

  • Cancer Center of Colorado at Sloan's Lake

    Denver, Colorado

  • Denver Health Medical Center

    Denver, Colorado

  • National Jewish Health-Main Campus

    Denver, Colorado

  • The Women's Imaging Center

    Denver, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Midtown

    Denver, Colorado

  • SCL Health Saint Joseph Hospital

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Rose

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • Mountain Blue Cancer Care Center - Swedish

    Englewood, Colorado

Showing 40 of 375 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.